Pfizer announces IES analysis of Aromasin in breast cancer recurrence

[News]

Pfizer today announced results from an exploratory analysis of the Intergroup Exemestane Study (IES) at a median follow-up of 91 months in estrogen-receptor positive (ER+) or estrogen-receptor unknown (ER-unknown) women that looked at breast cancer free survival (BCFS) and censored deaths that occurred prior to breast cancer relapse.

More... (http://www.news-medical.net/news/20091211/Pfizer-announces-IES-analysis-of-Aromasin-in-breast-cancer-recurrence.aspx)